Strides Pharma Science

Strides Pharma Science Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Strides Pharma Science (STAR.NS) as of Oct 16, 2026 is 19.04 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -992.65 % — a change of -101.92% (higher).

Cash Conversion

19.04 %

YoY

-101.92%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Strides Pharma Science is 2025 19.04 % . Cash Conversion Rate (OCF/Net Income) of Strides Pharma Science was 2024 -992.65 % . It decreases by -101.92% higher compared to the previous year.

The Strides Pharma Science Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
25.83 INR
Jan 1, 2019
18.50 INR
Jan 1, 2020
562.61 INR
Jan 1, 2021
179.37 INR
Jan 1, 2022
56.02 INR
Jan 1, 2023
-21.75 INR
Jan 1, 2024
-992.65 INR
Jan 1, 2025
19.04 INR
The Strides Pharma Science Cash Conversion history
YEARCash ConversionYoY
19.04 %-101.92%
-992.65 %+4,464.02%
-21.75 %-138.82%
56.02 %-68.77%
179.37 %-68.12%
562.61 %+2,940.68%
18.50 %-28.35%
25.83 %-141.19%
-62.70 %-175.95%
82.55 %+736.42%
9.87 %-157.50%
-17.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd, trading under the ticker symbol STAR.NS and identified by ISIN INE939A01011, is a prominent entity within the Indian healthcare sector, specifically operating in the pharmaceuticals industry. Headquartered in Bangalore, Karnataka, the company has established itself as a significant player in the global market for generic and bio-pharmaceutical products. Strides Pharma Science Ltd went public on February 3, 2000, marking a pivotal moment in its corporate history and allowing it to expand its operational footprint. The organization currently employs approximately 2,850 full-time staff members who are dedicated to the development, manufacture, and distribution of its diverse product portfolio. The company’s business activities are primarily divided into two main segments: Pharmaceutical and Bio-pharmaceutical. This structural division allows the firm to focus on both traditional generic drugs and more complex biological therapeutics, ensuring a balanced approach to meeting varied market demands. Geographically, Strides Pharma Science Ltd has a broad international presence, serving markets across Africa, Australia, Asia excluding India, North America, Europe, India, and other regions. This extensive reach is supported by a robust manufacturing infrastructure comprising eight distinct units. These facilities are strategically located to optimize supply chain efficiency and regulatory compliance. In India, the company operates two manufacturing sites in Bengaluru, along with additional facilities in Puducherry and Chennai. Beyond its domestic operations, Strides maintains manufacturing capabilities in Singapore, Milan, Italy, Florida, United States, and Nairobi, Kenya. This global network enables the company to produce a wide array of dosage forms, including liquids, creams, ointments, soft gels, sachets, tablets, and modified-release formats. Notably, the company is also engaged in the specialized manufacturing of soft gelatin capsules. The firm’s product development strategy emphasizes intellectual property-led niche products, distinguishing it from competitors who may focus solely on standard generics. The therapeutic areas covered by Strides Pharma Science Ltd are extensive, with a strong emphasis on drugs for anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, as well as other infectious diseases. This focus on high-impact therapeutic segments underscores the company’s commitment to addressing critical global health challenges. By combining a strong manufacturing base with a diverse product range and a global distribution network, Strides Pharma Science Ltd continues to play a vital role in the pharmaceutical landscape, providing essential medicines to patients worldwide while maintaining its position as a key player in the Indian stock market. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

Cash Conversion Rate (OCF/Net Income) of Strides Pharma Science is 19.04 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Strides Pharma Science changed from -992.65 % to 19.04 %, representing a -101.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Strides Pharma Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Strides Pharma Science

All Key Metrics — Strides Pharma Science